Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Net Margin (2016 - 2025)

Lineage Cell Therapeutics' Net Margin history spans 16 years, with the latest figure at 93.14% for Q4 2025.

  • For Q4 2025, Net Margin rose 2017.0% year-over-year to 93.14%; the TTM value through Dec 2025 reached 239.96%, down 4434.0%, while the annual FY2025 figure was 435.33%, 23971.0% down from the prior year.
  • Net Margin reached 93.14% in Q4 2025 per LCTX's latest filing, roughly flat from 92.91% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 56.02% in Q4 2021 to a low of 969.73% in Q2 2021.
  • Average Net Margin over 5 years is 302.45%, with a median of 214.88% recorded in 2022.
  • Peak YoY movement for Net Margin: surged 126936bps in 2021, then tumbled -37048bps in 2023.
  • A 5-year view of Net Margin shows it stood at 56.02% in 2021, then plummeted by -489bps to 330.08% in 2022, then soared by 32bps to 225.77% in 2023, then skyrocketed by 50bps to 113.32% in 2024, then rose by 18bps to 93.14% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Net Margin are 93.14% (Q4 2025), 92.91% (Q3 2025), and 698.95% (Q2 2025).